0.100
+0.005
(5.26%)
May 17 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.09 - 0.10 |
| 52 week | 0.06 - 0.44 |
| Open | 0.09 |
| Vol / Avg. | 33,000.00/117,566.00 |
| Mkt cap | 31.82M |
| P/E | - |
| Div/yield | - |
| EPS | -0.06 |
| Shares | 318.20M |
| Beta | 0.52 |
| Inst. own | - |
Events
Jun 25, 2013
METHYLGENE INC Annual and special meeting of Shareholders
- 10:00AM EDT -
May 13, 2013
Q1 2013 METHYLGENE INC Earnings Release
|
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | - | -314.59% |
| Operating margin | - | -314.59% |
| EBITD margin | - | -319.05% |
| Return on average assets | -108.13% | -45.75% |
| Return on average equity | -133.80% | -61.12% |
| Carbon Disclosure Rating | - | - |
Address
Suite 200, 7220 Frederick-Banting
MONTREAL, QC H4S 2A1
Canada
+1-514-3373333 (Phone)
+1-514-3370550 (Fax)
MONTREAL, QC H4S 2A1
Canada
+1-514-3373333 (Phone)
+1-514-3370550 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.
Officers and directors
| Martin Godbout Ph.D. | Chairman of the Board | |
| Charles M. Baum M.D., Ph.D. | President, Chief Executive Officer, Director | |
| Mark J. Gergen | Chief Operations Officer, Executive Vice President | |
| Rachel W. Humphrey M.D. | Chief Medical Officer, Executive Vice President | |
| Rodney Lappe Ph.D. | Director | |
| Peter A. Thompson M.D. | Director | |
| Henry J. Fuchs M.D., Ph.D. | Independent Director | |
| Peggy Mulligan | Independent Director |